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Abstract— HER2 is a protein that is essential to the process of differentiation, proliferation, tissue development and other 
physiological processes. HER-2 overexpression was occurred in 20-30% of breast cancer patients. Targeted therapies was performed 
using trastuzumab, on the basis of the examination by immunohistochemistry. Single nucleotide polimorphisme (SNP) Ile655Val were 
found on HER-2, which indicates the risk of cancer as well as a predictive factor of treatment with targeted therapies. The method 
had been used for HER-2 SNP detection is using TaqMan method which is expensive, or PCR RFLP which is cheaper and easier. 
148bp PCR product was widely used in PCR RFLP for HER-2 Ile655Val SNP detection confirmed at high concentration of agarose  
(3%). This study conducted to improve the PCR RFLP methods become more economical and more efficient by increasing the size of 
the PCR products confirmed with low concentration of agarose which have lower prices. The results showed that PCR RFLP method 
developed in this study, 480bp PCR product restricted with BsmAI  confirmed with 2% agarose,  has been successfully performed 
with cost effective and a high level of reproducibility. 
 




Cancer is one of the leading causes of death worldwide. In 
Indonesia, around 8,2juta deaths caused by cancer in 2012. 
Nationally, the prevalence of cancer in the population of all 
ages in Indonesia in 2013 amounted to 1.4 ‰ or estimated to 
be around 347.792 people. Cervical cancer and breast cancer 
is disease with the highest prevalence in Indonesia in 2013, 
which amounted to 0.8 ‰ of cervical cancer and breast 
cancer by 0.5 ‰. Based on Dharmais national cancer 
hospital data, during 2010-2013, breast cancer, cervical, lung, 
ovary, rectum, thyroid, colon, hepatoma, and 
nasopharyngeal cancer is known as the most common cancer.  
Breast cancer, cervical cancer and lung cancer are the three 
most common diseases, which the number of morbidity and 
mortality continues to increase [1], [2]. 
It is known that the cell growth cycle is controlled by 
various oncogenes and suppressor genes. Both of these 
genes products function as components in signal 
transduction which allows respond to a simulation of the 
outside of the cell. Abnormalities in oncogenes or suppressor 
genes will produce abnormal proteins with abnormal signal 
transduction functions that result in malignant 
transformation. It is can be assumed that cancer is not only 
caused by the uncontrolled cell growth but could also 
because of wrong signalling processes.  The signalling 
pathway not only regulate the growth but also regulate 
various cellular processes such as differentiation, 
angiogenesis, migration, apoptosis, inhibition of apoptosis, 
and etc. Some of important signaling molecules such as Ras 
/MAPK, HER-2/PIK3Ca / PTEN/Akt and others. Currently, 
the signal molecules were reported as a therapeutic target, as 
a potential prognostic biomarker. The use of molecules in 
the signaling pathway as a therapeutic target is currently 
applied in the implementation of the concept of personalized 
medicine [3], [4], [5]. 
Her-2 is a proto-oncogene consist of the receptor protein, 
trans membrane and tyrosine kinase. It is classified to the 
epidermal growth factor receptor (EGFR) which also known 
as HER family encoded by the genes her-2 on chromosome 
17q21. In normal conditions, these proteins together with 
other HER proteins form homodimers or heterodimers 
regulate a variety of cellular functions including cell 
proliferation. Overexpression of HER-2 occur in 20-30% of 
breast cancer cases. Breast cancer with HER-2 
overexpression is more aggressive and have a poor prognosis. 
Not only found in the breast cancer, overexpression of HER-
2 is also found in the ovarian, lung, and gastric carcinoma.  
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Monoclonal antibody trastuzumab is a targeted treatment for 
those overexpression HER-2 breast cancer patients  [6] – [9].  
As an antitumor agent, treatment with trastuzumab 
mechanism is not fully understood. Tratsuzumab been 
reported to induce antibody dependent cellular toxicity 
(ADCC), inhibits the cleavage domain of extracellular HER-
2, inhibit PIK3 / AKT, improve the localization of 
membrane PTEN, are the target of treatment based on a 
monoclonal antibody, trastuzumab. Recommended duration 
of trastuzumab treatment is one year of treatment according 
to the ESMO (European Society Medical Oncology). NCCN 
(National comprehensive Cancer Network) and St. Gallen, 
also recommends treatment with trastuzumab at the same 
duration for this type of breast cancer. Costs incurred for the 
purchase of monoclonal antibody trastuzumab per ampoule 
for each month usage is in the range of thirty million rupiahs. 
Since the prize quite expensive, it is need mature 
consideration for trastuzumab treatment. 
Immunohistochemistry methods are not enough used as a 
basis for treatment with trastuzumab. It is reported that 
single nucleotide polymorphism at the trans membrane 
domain HER-2 Ile655Val can be used as the area to know 
receptor-drug interaction, drug susceptibility, receptor 
topology. Thus it can be used as a predictive factor of the 
patient's response to treatment monoclonal antibody 
trastuzumab. It was reported that trastuzumab were more 
effective to patients with overexpression of HER-2 
Ile655Val genotype homozygous. The risk of cardiotoxicity 
will be found in patients with heterozygous Ile655Val   
[10] – [19]. 
There are several methods for the single-nucleotide 
polymorphisms (SNPs), from the simple way to the complex 
ones.  In several study, HER-2 Ile655Val, was reported 
tested using TaqMan allelic discrimination which are 
expensive.  The popular methods for HER-2 Ile655Val 
genotyping which are no special equipment, easy to design, 
simple and inexpensive is PCR-RFLP. The presence or 
absence of the restriction enzyme recognition site result in 
the formation of restriction fragments of different sizes, 
allele identification which can be done by the electrophoretic 
fragments separation. In some reports, most of the PCR 
RFLP of HER-2 Ile655Val genotyping were done with 
148bp PCR fragment, continue with digestion of each PCR 
product with BsmAI, which gives 116 and 32 bp fragments 
for the Val allele and 148bp fragment for the Ile Allele. The 
PCR product cut result will be too short and should be 
separate in the high concentration of agarose (3% agarose). 
This will increase the cost service of the HER-2 SNP 
detection with PCR-RFLP methods. Here in this research 
were conducted to improve the HER-2 PCR-RFLP A to G 
transition (Ile655Val) methods in order for cost effective of 
HER-2 SNP detection by increasing the PCR product size 
confirmed in low concentration of agarose  [20] - [23].  
II. MATERIALS AND METHODS 
A. Materials 
The research was conducted using ethical clearance issued 
by Indonesia Ministry of Health . Breast cancer tissue was 
provided from several hospital in West Sumatera province in 
Indonesia. The fresh tissue samples were stored at -80 ° C.  
B. HER2 Breast Cancer Tissue Genome Extraction 
DNA genom of breast cancer tissue were extracted 
according to the procedure PureLink® DNA genome 
extraction kit from Invitrogen. The DNA genome extraction 
were then confirmed in 1% agarose gel  
C. HER-2 PCR Amplification 
HER-2 PCR amplification were amplified with below 
PCR mixed: 22µL Thermo Scientific Nuclease-Free Water, 
25µL Thermo Scientific DreamTaq Green PCR Master Mix 
(2x), 1µL Forward Primer (5'-TGA TCT GCC CAC AGA 
CTC-3 ') and 1µL Reverse Primer (5'-TCT CAT CGT CCG 
CTT GTA CC-3') and genome template. PCR was 
performed using a thermo cycler (Kyratec’s SuperCycle, 
Republic of Korea) under the following PCR conditions: 
Initian denaturation of 5 min at 95 ° C, 35 cycles of 30 
seconds at 95 ° C (denaturation), 30 seconds at 55 ° C 
(annealing), 1 mins at  72 ° C (extension), followed by a 
final extension for 5mins at  72 ° C. PCR product were 
confirmed in 1% agarose stained with EtBR.  
D. DNA Sequencing 
DNA sequencing were done based on the Sanger’s 
method , with ABI 3100 Genetic Analyzer Applied 
conducted by PT . Genetic Science. Sequencing result than 
was analysed with BLAST program for gene identification.  
E. Sample Preparation, optimization digestion and analyze 
data 
480bp PCR product were purified with the Wizard SV 
gel and PCR clean up system kit. The purification methods 
were following the protocol from the manufactures.  Pured 
DNA PCR product 480bpwere restricted with BsmAI, and 
incubated at several incubation time  15 min, 30 min, 45 min, 
1 hour and 3 hours, incubated at 55 ° C. The BsmAI 
restricted result than were electrophoresis with 2 different 
concentrations of agarose, 1.5 % compared with 2 % agarose. 
Restricted product 480bp DNA fragment were separated 
with optimum agarose gel. Restricted enzyme BsmAI will 
not cut 480bp DNA target if there was no SNP. 376bp and 
104bp DNA fragment will produced if there was 
homozygous SNP. While for the heterozygous SNP will 








III. RESULT AND DISCUSSION 
A. PCR HER2 transmembrane domain with the Target 
Product 480bp 
For optimization of PCR conditions were used gradient 
















Fig. 2. Optimization of PCR by using using Thermo Scientific DreamTaq 
Green (right). DNA samples were amplified shows 480bp size. 
 
From the above results optimization of PCR using 
annealing temperature gradient between 50 ° C to 60 ° C, 
55oC shown  as the best  annealing temperature at 480bp 
corresponding to the target. The PCR product then 
confirmed with sequencing methods, and shown as targeted 
ones. (data was not shown). 
B. PCR RFLP optimization 
The optimization process conducted on the optimization 
of incubation time were: 15 min, 30 min, 45 min, 60 min and 
180 min, incubated at 55 ° C. Process optimization was 
performed using the known constituent sequence DNA 
sample nucleotides, non SNP HER-2 and heterozygous SNP 
HER-2. The BsmAI restricted result than were 
electrophoresis compared between 2 different concentrations 






















Fig. 3. RFLP Using 4 Incubation Time In contrast to Sample No. 1 and 2 
with Marker 1kb DNA Ladder Plus, Agarose 1.5 % (above) and  Agarose 
2 % (below) 
From figure 3 and 4 can be seen that the BsmAI restricted 
the DNA template and separated well at 2 % agarose 
accordance to the known  DNA sequence template. The 
incubation time did not show a significant difference in each 
incubation time: 15, 30, 45 and 60min. Furthermore  180 
min incubation time the restricted DNA shown fade, this is 
possible because the some of the DNA template partially 
degraded during the incubation. It is suggested incubation 
time for BsmAI restricted DNA were in 15 min incubation, 


















Fig 4. RFLP using 3 Incubation Time In contrast to Sample No. 1 and 2 
with Marker 100bp DNA Ladder, Agarose 2 % .  
 
Based on those optimization condition, another 30 DNA 
sample of breast cancer then were PCR, purified, and 
restricted. The result was shown in below figure. Those 30 
DNA sample were had been checked for the sequence for 




















Fig. 5. Some of purified PCR product (above) and PCR RFLP result  
electrophoresis with 2 % Agarose (below). 
 
Comparing with the sequence result, shown 100% same 
result as those PCR RFLP result which developed in this 
research.  
Human epidermal growth factor receptor (HER-2) is 
located on chromosome 17q21 and encodes a 
transmembrane glycoprotein exhibiting tyrosine kinase 
activity. Overexpression of HER-2 has been observed in 20-
30% of breast cancer, and associated with poor prognosis. 
Immunohistochemistry (IHC) is the most widely used 
480bp 
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methods for the HER-2 overexpression detection. Based on 
IHC result than as the basis of recommendation for the 
targeted therapy for those patients. Humanized monoclonal 
antibody trastuzumab was HER-2 targeted therapy approved 
for clinically use. Trastuzumab show clinical benefit, but in 
many patients HER-2 over expressing do not shown respond 
to these agents {[9], [18], [19]}. Additional diagnostic 
method was needed for identifying patient for targeted 
therapy.  
PCR-RFLP is a popular method for SNP or mutation 
genotyping. PCR RFLP methods need no special equipment, 
easy to design, simple and inexpensive. In some report 
shown that PCR RFLP has been applied for the detection of 
mutations associated with tumorigenesis. This method has 
been successfully applied for N-ethyl-N-nitosourea-induced 
mutation in codon 12 of cH-rasl (MspI site 1695-1698) and 
codon 248 of the p53 tumor suppressor gene (MspI site from 
14,067 to 14,070) in human skin fibroblasts [25]. For PCR-
RFLP HER-2, also have been reported by several researcher 
which then confirmed in 3% agarose for PCR-RFLP  {[26], 
[27], [28]}. The high concentration of agarose will increase 
the cost of HER-2 genotyping. In development countries 
such as Indonesia, lower cost for detection were very 
consider and needed. Standard protocol for PCR-RFLP 
HER-2 than were improved by reducing the agarose 
concentration by increasing the size of the PCR products 
amplified HER-2 into 480bp. Restricted enzyme BsmAI will 
not cut 480bp DNA target if there was no SNP. 376bp and 
104bp DNA fragment will produced if there was 
homozygous SNP. While for the heterozygous SNP will 
produce 480bp, 376bp and 104bp DNA fragment.  
In order to get faster result of HER-2 PCR-RFLP, 
optimization also performed by optimization of the restricted 
enzyme incubation times. As the result of optimization, 15 
minutes as the best incubation time and 2% agarose as best 
agarose concentration to distinguish homozygous or 
heterozygous genotypes. In below Table was shown the 
timeframe in each step of HER-2 PCR RFLP 
 
TABLE I 
TIME FRAME IN EACH STEP OF HER-2 PCR-RFLP ANALYSIS 
Procedure Time required (min) 
DNA extraction 
PCR amplification 
• Set up 
• incubation 
Restriction digestion 
• Set up 
• Incubation 
Gel electrophoresis 
• Gel set up 
• Run  













The time needed for genotyping HER2 to determine HER 
SNP is approximately 4 hours, with shown high 
reproducibility. Other 30 breast cancer patient which treated 
with HER-2 PCR RFLP optimize conditions obtained in this 
study notify 100% the same result as sequencing. Results of 
the study then could be recommended to be applied to the 
HER-2 genotyping, assist the oncologist in determining a 
right patient getting the right targeted therapy to support 
personalized medicine. This improved PCR RFLP method 
could be useful for clinical and epidemiological purposes. 
IV. CONCLUSIONS 
HER-2 PCR-RFLP methods have been succeed improved 
to be cost effective by increasing the PCR product in order to 
decrease the agarose concentration. Improved HER-2 PCR 
RFLP shown high reproducibility, 100% similarity as 
sequence results.  
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